SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.

Published in:

Leukemia (08876924), 2013, v. 27, n. 1, p. 130, doi. 10.1038/leu.2012.169

By:

• Hansen, N;
• Ågerstam, H;
• Wahlestedt, M;
• Landberg, N;
• Askmyr, M;
• Ehinger, M;
• Rissler, M;
• Lilljebjörn, H;
• Johnels, P;
• Ishiko, J;
• Melo, J V;
• Alexander, W S;
• Bryder, D;
• Järås, M;
• Fioretos, T

Publication type:

Article